BCL2 and breast carcinoma: A study of the treatment combining antisense BCL-2 with HER2 oligonucleotide in different breast cancer cell lines also showed emerging results, not only suppressing the expression of BCL-2 and pAKT, but also enhancing anticancer drug sensitivity [263].